| scholarly article | Q13442814 |
| P2093 | author name string | Chieko Mineo | |
| Philip W Shaul | |||
| P2860 | cites work | Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase | Q43568413 |
| Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster | Q44189585 | ||
| Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. | Q46591794 | ||
| Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome? | Q46677340 | ||
| FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase | Q46790570 | ||
| Endothelial function is impaired in patients with primary antiphospholipid syndrome | Q46794129 | ||
| Patients with antiphospholipid syndrome display endothelial perturbation | Q58418462 | ||
| Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis | Q58622036 | ||
| Platelet adhesion to dimeric β2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibαand apolipoprotein E receptor 2′ | Q63346659 | ||
| Nitric oxide and vascular disease | Q71698392 | ||
| Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study | Q73491960 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| Flow-mediated arterial dilation in primary antiphospholipid syndrome | Q81014753 | ||
| Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change | Q81441260 | ||
| Cardiac manifestations in antiphospholipid syndrome | Q28211851 | ||
| Regulation of endothelial nitric oxide synthase: location, location, location | Q28217344 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. | Q30497721 | ||
| GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. | Q33329778 | ||
| The use of low-molecular-weight heparins in pregnancy--how safe are they? | Q33377391 | ||
| Nitric oxide insufficiency, platelet activation, and arterial thrombosis | Q34234301 | ||
| Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? | Q34443514 | ||
| Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I | Q34467454 | ||
| Reelin, lipoprotein receptors and synaptic plasticity | Q34575575 | ||
| How I treat the antiphospholipid syndrome | Q34991343 | ||
| Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome | Q35158386 | ||
| Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention | Q35172201 | ||
| Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome | Q35874202 | ||
| Nitric oxide insufficiency and atherothrombosis | Q35874972 | ||
| Inflammatory response and the endothelium. | Q35928642 | ||
| Beta 2 glycoprotein I--function in health and disease | Q35928646 | ||
| Beta2-glycoprotein I and LDL-receptor family members. | Q35928715 | ||
| Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies | Q35928725 | ||
| Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model | Q36300619 | ||
| Current concepts on the pathogenesis of the antiphospholipid syndrome | Q36598158 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms | Q37249524 | ||
| Autoimmune-mediated atherothrombosis | Q37283009 | ||
| Platelets and the antiphospholipid syndrome | Q37283013 | ||
| Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome | Q37318783 | ||
| Nitric oxide released from activated platelets inhibits platelet recruitment | Q37369997 | ||
| Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? | Q37510353 | ||
| Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? | Q37721617 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. | Q40249655 | ||
| Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites | Q40681189 | ||
| Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome | Q42871186 | ||
| P433 | issue | 1-2 | |
| P304 | page(s) | e47-e52 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Drug discovery today. Disease mechanisms | Q27721894 |
| P1476 | title | New Insights into the Molecular Basis of the Antiphospholipid Syndrome | |
| P478 | volume | 8 |
| Q94940476 | Antiphospholipid Syndrome |
| Q37699576 | Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications |
| Q33406588 | Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis |
| Q34623779 | Recurrent, spontaneous esophageal ruptures associated with antiphospholipid antibody syndrome: report of a case |
| Q86911419 | [Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke] |
Search more.